Payment overview · 2025
General Payments
$553.69
10 reported records · 5 companies
Healthcare provider profile · identity verified
Abdul Butman, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ENGLEWOOD, OH · NPI 1912953472
Verified facts
What the public records show
CMS Open Payments records show Abdul Butman, MD received $553.69 in general payments during 2025 across 10 reported records.
Novo Nordisk Inc accounted for 30.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 318 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 318 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $169.22 | 30.6% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.22 | 22.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $124.22 | 22.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $121.83 | 22.0% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.20 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $553.69 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $161.49 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $124.22 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $124.22 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $121.83 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $41.89 | 4 | 2025 |
Source payment records
|
|||||
| Sotyktu Normalized: sotyktu |
Drug | E.R. Squibb & Sons, L.L.C. | $14.20 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $7.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 318 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 172 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
318 | 63 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
201 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
318 | 63 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
172 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
201 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1303 | 364 |
| Amlodipine Besylate | Amlodipine Besylate | 760 | 200 |
| Losartan Potassium | Losartan Potassium | 624 | 168 |
| Levothyroxine Sodium | Levothyroxine Sodium | 555 | 155 |
| Furosemide | Furosemide | 477 | 122 |
| Ezetimibe | Ezetimibe | 465 | 138 |
| Metformin Hcl | Metformin Hcl | 465 | 128 |
| Metoprolol Tartrate | Metoprolol Tartrate | 431 | 116 |
| Omeprazole | Omeprazole | 431 | 116 |
| Lisinopril | Lisinopril | 419 | 110 |
| Glimepiride | Glimepiride | 383 | 87 |
| Allopurinol | Allopurinol | 330 | 92 |
| Jardiance | Empagliflozin | 318 | 63 |
| Gabapentin | Gabapentin | 317 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 254 | 62 |
| Nifedipine Er | Nifedipine | 252 | 58 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 246 | 64 |
| Simvastatin | Simvastatin | 240 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 238 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 238 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 230 | 73 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 212 | 50 |
| Trazodone Hcl | Trazodone Hcl | 207 | 50 |
| Eliquis | Apixaban | 201 | 38 |
| Sertraline Hcl | Sertraline Hcl | 193 | 51 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 189 | 50 |
| Potassium Chloride | Potassium Chloride | 184 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 178 | 55 |
| Ozempic | Semaglutide | 172 | 32 |
| Buspirone Hcl | Buspirone Hcl | 170 | 42 |
| Metformin Hcl Er | Metformin Hcl | 154 | 41 |
| Ipratropium Bromide | Ipratropium Bromide | 152 | 76 |
| Pravastatin Sodium | Pravastatin Sodium | 152 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 44 |
| Januvia | Sitagliptin Phosphate | 147 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 141 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 138 | 29 |
| Alendronate Sodium | Alendronate Sodium | 136 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 136 | 47 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 135 | 26 |
| Montelukast Sodium | Montelukast Sodium | 134 | 35 |
| Meloxicam | Meloxicam | 130 | 33 |
| Spironolactone | Spironolactone | 129 | 27 |
| Carvedilol | Carvedilol | 121 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 108 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 100 | 25 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 100 | 24 |
| Donepezil Hcl | Donepezil Hcl | 96 | 29 |
| Synthroid | Levothyroxine Sodium | 96 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 96 | 25 |
| Doxazosin Mesylate | Doxazosin Mesylate | 95 | 25 |
| Valsartan | Valsartan | 89 | 22 |
| Finasteride | Finasteride | 88 | 23 |
| Clonidine Hcl | Clonidine Hcl | 87 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 86 | 40 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 86 | 22 |
| Celecoxib | Celecoxib | 80 | 29 |
| Azithromycin | Azithromycin | 74 | 66 |
| Humalog Kwikpen U-100 | Insulin Lispro | 72 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 70 | 15 |
| Calcitriol | Calcitriol | 70 | 22 |
| Lovastatin | Lovastatin | 69 | 20 |
| Methocarbamol | Methocarbamol | 67 | 20 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 66 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | 12 |
| Famotidine | Famotidine | 65 | 20 |
| Atenolol | Atenolol | 64 | 20 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 58 | 13 |
| Fenofibrate | Fenofibrate | 55 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 54 | 15 |
| Klor-Con M20 | Potassium Chloride | 54 | 16 |
| Trulicity | Dulaglutide | 52 | 12 |
| Bumetanide | Bumetanide | 51 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 14 |
| Xarelto | Rivaroxaban | 51 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 49 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 47 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 44 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 44 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 36 |
| Meclizine Hcl | Meclizine Hcl | 41 | 15 |
| Colchicine | Colchicine | 39 | 13 |
| Torsemide | Torsemide | 38 | suppressed |
| Novolog Flexpen | Insulin Aspart | 37 | 11 |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 33 |
| Prednisone | Prednisone | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 29 |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Myrbetriq | Mirabegron | 28 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 27 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Nabumetone | Nabumetone | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Cephalexin | Cephalexin | 25 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 24 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 19 |
| Clobetasol Propionate | Clobetasol Propionate | 22 | 14 |
| Methylprednisolone | Methylprednisolone | 22 | 19 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | 13 |
| Clonazepam | Clonazepam | 21 | suppressed |
| Jantoven | Warfarin Sodium | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 20 | 19 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 14 |
| Glipizide | Glipizide | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 18 | 18 |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Admelog Solostar | Insulin Lispro | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Alprazolam | Alprazolam | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Desoximetasone | Desoximetasone | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Latanoprost | Latanoprost | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Febuxostat | Febuxostat | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $553.69 · 10 records | Novo Nordisk Inc | JARDIANCE, KISUNLA, Ozempic, Rybelsus, Sotyktu, VYNDAQEL, Wegovy | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error